Adjuvant-driven epitope hierarchy correlates with the protective efficacy of FimA vaccine against Klebsiella pneumoniae
By
Guangyang Ming
Longlong Chen
Pengju Yan
Xiaoqiong Wang
Zhifu Chen
Qiang Gou
Yue Yuan
Jiayi Chen
Haiming Jing
Ping Luo
Quanming Zou
Jinyong Zhang
Zhiyong Liu
Renjian Hu
Zhuo Zhao
June 22, 2026
Clinical Scorecard: Influence of Adjuvants on the Hierarchical Structure of FimA Epitopes and Its Impact on Vaccine Efficacy Against Klebsiella pneumoniae
At a Glance
Category Detail
Condition Klebsiella pneumoniae infections Key Mechanisms Adjuvants modulate immunodominant B-cell epitope hierarchies of FimA, enhancing protective immunity. Target Population Individuals at risk of Klebsiella pneumoniae infections, particularly in healthcare settings. Care Setting Vaccine development and clinical immunization studies.
Key Highlights
AddaS03 adjuvant led to 100% survival in murine models against hvKP. Different adjuvants resulted in varying opsonophagocytic killing activities. Identification of three novel immunodominant epitopes of FimA. Combination of FimA epitopes with AlPO4 achieved 80% protection rate. Adjuvants significantly enhance anti-FimA immunity. Guideline-Based Recommendations
Diagnosis
Monitor for Klebsiella pneumoniae infections in at-risk populations. Management
Consider vaccine development targeting FimA with appropriate adjuvants. Monitoring & Follow-up
Evaluate humoral immune responses post-vaccination. Risks
Be aware of multidrug-resistant Klebsiella pneumoniae strains. Patient & Prescribing Data
Patients at risk for Klebsiella pneumoniae infections, especially in hospital settings.
Potential for FimA-based vaccines to improve immunity against hvKP.
Clinical Best Practices
Select adjuvants that enhance immunogenicity of vaccine candidates. Focus on the identification of immunodominant epitopes for effective vaccine design. Conduct further studies to evaluate the efficacy of FimA-based vaccines in diverse populations. Related Resources & Content
